

# SECURITIES AND EXCHANGE COMMISSION

## FORM 8-K

Current report filing

Filing Date: **1995-02-22** | Period of Report: **1995-02-22**  
SEC Accession No. [0000010081-95-000004](#)

([HTML Version](#) on [secdatabase.com](#))

### FILER

#### **BARR LABORATORIES INC**

CIK: **10081** | IRS No.: **221927534** | State of Incorporation: **NY** | Fiscal Year End: **0630**  
Type: **8-K** | Act: **34** | File No.: **001-09860** | Film No.: **95514220**  
SIC: **2834** Pharmaceutical preparations

Business Address  
2 QUAKER RD BOX D2900  
POMONA NY 10970  
9143621100

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act  
of 1934

Date of Report February 22, 1995

BARR LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

New York

1-9860

22-1927534

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

Two Quaker Road, P.O. Box 2900, Pomona, New York

10970-0519

(Address of principal executive offices)

(Zip code)

(914) 362-1100

(Registrant's telephone number, including area code)

BARR LABORATORIES, INC.

CURRENT REPORT dated February 22, 1995

Item 5. Other Events

On February 17, 1995, the Registrant completed the conversion of the entire \$10 million principal amount of all outstanding 10.05% Convertible Subordinated Notes to 510,358 common shares of Barr Laboratories stock. The noteholders informed the Registrant that the shares, received for the conversion, were privately placed.

Item 7. Financial Statements, and Exhibits

(c) Exhibits

1. Registrant's February 13, 1995 press release announcing that its noteholders had elected to convert the entire \$10 million principal amount of all outstanding 10.05% Convertible Subordinated Notes to common shares of Barr Laboratories stock.

BARR LABORATORIES, INC.

CURRENT REPORT dated February 22, 1995

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BARR LABORATORIES, INC.

Date: February 22, 1995 /S/ Paul M. Bisaro  
Paul M. Bisaro  
Vice President, Chief Financial  
Officer, General Counsel and Corporate  
Secretary

BARR LABORATORIES, INC.

CURRENT REPORT dated February 22, 1995

EXHIBIT INDEX

The following exhibit is filed with this Report:

Exhibit No.	Description
99	Registrant's press release dated February 13, 1995.

[ARTICLE] 5

Barr Laboratories, Inc.  
2 Quaker Road, P.O. Box 2900  
NEWS RELEASE  
Pomona, NY 10970  
914-362-1100

CONTACT: Charles M. Mayr, 914-348-8050

## Barr Laboratories Announces Conversion of Debt to Common Stock

Pomona, New York, February 13, 1995.....Barr Laboratories, Inc. (AMEX-BRL) today announced that its noteholders have elected to convert the entire \$10 million principal amount of all outstanding 10.05% Convertible Subordinated Notes to common shares of Barr Laboratories stock. The noteholders will receive approximately 510,000 shares. Barr expects that the transaction will be completed within ten days. The noteholders have informed the Company that the shares, received for the conversion, are expected to be privately placed.

Although the Convertible Subordinated Notes were due June 28, 2001, Barr elected to prepay the debt so that the noteholders had the option of taking common stock or a cash payment equivalent to \$10 million plus a make-whole amount of approximately \$750,000.

Barr Laboratories, Inc. is a leading independent developer, manufacturer and marketer of high quality generic pharmaceuticals. The Company manufactures and distributes a wide range of generic prescription drug products in various dosage forms and strengths. Barr's administrative offices and research and development, manufacturing and distribution facilities are located in Blauvelt and Pomona, New York, and Northvale, New Jersey.